Qudexy XR (Topiramate) Patent Expiration, LOE Window & CMS Spending
Qudexy XR (Topiramate) by Upsher Smith Laboratories: FDA Orange Book LOE 2033-03-19, 15 AB generics, $5.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Upsher Smith Laboratories |
| FDA Application & Pathway | N205122 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-03-19 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 15 |
| 2024 CMS Total Public Spend | $5.0M |
| 2024 Medicare Part D Spend | $1.2M |
| 2024 Medicaid Spend | $3.8M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |